FDA Approves Drug To Manage Canine Obesity

Pfizer Animal Health’s canine obesity management drug, Slentrol, has been approved by the FDA.

The U.S. Food and Drug Administration has approved Pfizer Animal Health’s Slentrol (dirlotapide) for the management of canine obesity. This is the first veterinary-approved obesity drug for dogs in the United States, according to the company.

Pfizer said that it developed Slentrol in response to the unmet need for a medication to help veterinarians and pet owners manage canine obesity in a comprehensive program that includes healthy diet and appropriate exercise.

“Veterinarians will now have the additional option of using Slentrol in conjunction with diet and exercise,” said S. Kristina Wahlstrom, VMD, Pfizer Animal Health.

Slentrol, which decreases a dog’s appetite, is given once daily as an oral solution. It will be available to veterinarians this spring.

Slentrol should not be used in cats, dogs receiving long-term corticosteroid therapy or dogs with liver disease.

<HOME>

Leave a Comment

Comments

Your email address will not be published. Required fields are marked *

___

Register

Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).
 

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.